公开(公告)号：US20180193312A1

公开(公告)日：2018-07-12

申请号：US15658719

申请日：2017-07-25

申请人： ChronoSyn, LLC

发明人： Mark Herbert Swanson ,  Paula A Witt-Enderby

IPC分类号： A61K31/4045 ,  A61K31/593 ,  A61K31/122 ,  A61K31/194 ,  A61P19/10 ,  A61P15/00 ,  A23L33/155

CPC分类号： A61K31/4045 ,  A23L33/10 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A23V2200/306 ,  A23V2250/7106 ,  A23V2250/7144 ,  A61K31/122 ,  A61K31/194 ,  A61K31/593 ,  A61P15/00 ,  A61P19/10 ,  A23V2250/1632 ,  A23V2250/30

摘要： The present invention is a nutraceutical formulation, intended for oral administration, comprising co-administered if not co-formulated melatonin together with at least one of strontium, Vitamin D, and Vitamin K or their analogues. The nutraceutical combination or formulation is designed to be taken by mouth within about two hours prior to bedtime, and in fact should not be taken at any other time. The combination therapy gives new and unexpectedly improved results compared to the administration of melatonin alone.

公开(公告)号：US09968643B2

公开(公告)日：2018-05-15

申请号：US15331346

申请日：2016-10-21

申请人： BIOGAIA AB ,  Michigan State University

发明人： Eamonn Connolly ,  Robert Allen Britton ,  Laura Rae McCabe

IPC分类号： A61K35/747 ,  C12N1/20 ,  C12Q1/68 ,  A23L33/135 ,  A61K35/00

CPC分类号： A61K35/747 ,  A23L33/135 ,  A23V2002/00 ,  A61K2035/11 ,  C12N1/20 ,  C12Q1/689 ,  C12Q2600/156 ,  C12Q2600/16 ,  A23V2200/306 ,  A23Y2220/00 ,  A23Y2220/71

摘要： The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.

公开(公告)号：US09821014B2

公开(公告)日：2017-11-21

申请号：US13993182

申请日：2011-12-14

申请人： Alexandra Fregonese

发明人： Alexandra Fregonese

IPC分类号： A61K9/14 ,  A61K35/64 ,  A61K8/26 ,  A61K8/97 ,  A61K33/06 ,  A61K35/02 ,  A61Q19/00 ,  A23L21/20 ,  A23L33/16

CPC分类号： A61K35/64 ,  A23L21/20 ,  A23L33/16 ,  A23V2002/00 ,  A61K8/26 ,  A61K8/9706 ,  A61K33/06 ,  A61K35/02 ,  A61K35/63 ,  A61Q19/00 ,  A61K2300/00 ,  A23V2200/306 ,  A23V2250/1564 ,  A23V2250/1628

摘要： The present invention relates to complexes of beepollen and clay, as well as to their preparation methods and to their therapeutic uses or as a food supplement, a functional food, in human and animal healthcare.

公开(公告)号：US20170296468A1

公开(公告)日：2017-10-19

申请号：US15515883

申请日：2015-10-01

申请人： NOFIMA AS

发明人： Jurgen Schrezenmeir ,  Svein Halvor Knutsen ,  Simon Ballance

IPC分类号： A61K9/00 ,  A23L2/52 ,  A23L33/30 ,  A23L2/84 ,  A61K33/06 ,  A61K33/00

CPC分类号： A61K9/0095 ,  A23L2/52 ,  A23L2/84 ,  A23L33/30 ,  A23V2002/00 ,  A61K31/191 ,  A61K33/00 ,  A61K33/06 ,  A23V2200/306 ,  A23V2200/322 ,  A23V2200/3322 ,  A23V2250/04 ,  A23V2250/1578 ,  A23V2250/161 ,  A61K2300/00

摘要： The present invention provides a sugar-depleted fruit or vegetable juice product, wherein said juice product is a fruit or vegetable juice or juice-retaining fruit or vegetable derived matter, wherein said juice product contains at least about 5 g/l gluconic acid and said juice product contains any two or three, of (i) at least about 0.5 g/l Ca2+, (iii) at least about 1 g/l K+, and (iii) at least about 0.1 g/l Mg2+. Also provided are methods of producing the same and the use thereof to assist in maintaining the health and well-being of a subject and in the treatment and prevention of medical ailments, specifically those associated with the over-consumption of glucose and/or sucrose or inappropriate metabolism of glucose, e.g. metabolic syndrome, diabetes mellitus type II, obesity, dyslipidemia, insulin resistance, hypertension and liver steatosis.

公开(公告)号：US20170056443A1

公开(公告)日：2017-03-02

申请号：US15351037

申请日：2016-11-14

申请人： Delavau LLC

发明人： Kevin W. Lang ,  Gregory B. Murphy ,  Gregory E. Urbanski

IPC分类号： A61K33/10 ,  A61K31/59 ,  A23P10/28 ,  A23L33/155 ,  A23L33/00 ,  A61K9/20 ,  A61K9/00

CPC分类号： A61K33/10 ,  A23L33/155 ,  A23L33/16 ,  A23L33/40 ,  A23P10/28 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/59 ,  A61K31/593 ,  A61K45/06 ,  A23V2200/254 ,  A23V2200/306 ,  A23V2250/063 ,  A23V2250/1578 ,  A23V2250/71 ,  A61K2300/00

摘要： Dietary calcium supplements comprising highly bioavailable forms of calcium carbonate and methods of using these calcium carbonate forms to improve calcium balance, strengthen bones, and prevent, treat, and/or ameliorate bone loss associated with osteoporosis are provided.

摘要翻译： 提供了包含高度生物可利用形式的碳酸钙的膳食钙补充剂和使用这些碳酸钙形式来改善钙平衡，加强骨骼以及预防，治疗和/或改善与骨质疏松症相关的骨丢失的方法。

公开(公告)号：US20170020921A1

公开(公告)日：2017-01-26

申请号：US15288210

申请日：2016-10-07

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

发明人： Charles Y.C. Pak ,  Khashayar Sakhaee ,  Orson W. Moe

IPC分类号： A61K33/06 ,  A61K31/194 ,  A23L33/00 ,  A61K9/08 ,  A23L2/40 ,  A23L2/52 ,  A61K33/10 ,  A61K9/00

CPC分类号： A61K33/06 ,  A23K20/24 ,  A23L2/40 ,  A23L2/52 ,  A23L33/16 ,  A23L33/30 ,  A23V2002/00 ,  A23V2200/00 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/194 ,  A61K33/08 ,  A61K33/10 ,  A23V2200/306 ,  A23V2250/032 ,  A23V2250/1578 ,  A23V2250/161 ,  A61K2300/00

摘要： Disclosed is an effervescent preparation of calcium and magnesium with additional citric acid in a defined ratio. Also disclosed is the use of these compositions to raise cardioprotective citrate and magnesium in serum to help prevent heart attacks from calcium supplements, and to provide bioavailable calcium and magnesium to prevent osteoporosis-related fractures and low blood magnesium from the use of proton pump inhibitors.

摘要翻译： 公开了具有规定比例的额外柠檬酸的钙和镁的泡腾制剂。 还公开了使用这些组合物来提高血清中的心脏保护性柠檬酸盐和镁，以帮助防止钙补充剂的心脏病发作，并提供生物可利用的钙和镁以防止使用质子泵抑制剂引起骨质疏松症相关骨折和低血镁。

公开(公告)号：US09522178B2

公开(公告)日：2016-12-20

申请号：US14418257

申请日：2012-07-31

申请人： Aiko Ohmachi ,  Hiroaki Matsuyama ,  Yoshikazu Morita ,  Yuko Ishida ,  Takayuki Nara ,  Ken Kato ,  Atsushi Serizawa ,  Hiroshi Ueno ,  Hiroshi Urazono

发明人： Aiko Ohmachi ,  Hiroaki Matsuyama ,  Yoshikazu Morita ,  Yuko Ishida ,  Takayuki Nara ,  Ken Kato ,  Atsushi Serizawa ,  Hiroshi Ueno ,  Hiroshi Urazono

IPC分类号： A23C9/152 ,  A61K38/46 ,  A23C9/12 ,  A23C9/13 ,  A23C9/146 ,  A23C9/16 ,  A61K9/00 ,  A61K38/44 ,  A61K38/18 ,  A61K38/01 ,  A61K9/16

CPC分类号： A61K38/465 ,  A23C9/1213 ,  A23C9/1216 ,  A23C9/1322 ,  A23C9/1465 ,  A23C9/1526 ,  A23C9/16 ,  A23V2002/00 ,  A23V2200/00 ,  A61K9/0095 ,  A61K9/1664 ,  A61K38/012 ,  A61K38/1891 ,  A61K38/443 ,  C12Y111/01007 ,  C12Y301/27 ,  A23V2200/30 ,  A23V2200/306 ,  A23V2250/55 ,  A61K2300/00

摘要： The invention relates to a powdered milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 1.4 to 24 mg/15 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.35 to 10.

摘要翻译： 本发明涉及一种粉末状乳制品，其含量为1.4〜24mg / 15g的血管生成素和/或血管生成素水解物，以及与血管生成素和/或血管生成素水解物的质量比为0.35〜10的乳过氧化物酶和/或乳过氧化物酶水解物 。

公开(公告)号：US09346863B2

公开(公告)日：2016-05-24

申请号：US14090603

申请日：2013-11-26

申请人： COMPAGNIE DES PECHES SAINT MALO SANTE

发明人： Hubert Drieu La Rochelle ,  Elisa Courois

IPC分类号： A23L1/305 ,  C07K14/46 ,  A23J3/34 ,  A61K35/60 ,  A61K38/01 ,  C12P21/06

CPC分类号： C07K14/461 ,  A23J3/346 ,  A23L33/18 ,  A23V2002/00 ,  A61K35/60 ,  A61K38/012 ,  C12P21/06 ,  A23V2250/543 ,  A23V2200/306

摘要： The present invention relates to a fish protein hydrolysate having a biological activity of interest, in particular an effect on the stimulation and maintenance of bone. The fish protein hydrolysate is characterized in that it is obtained by enzymatic hydrolysis of at least one protein source selected from the fish species Micromesistius poutassou, Clupea harengus, Scomber scombrus, Sardina pilchardus, Trisopterus esmarki, Trachurus spp, Gadus morhua, Pollachius virens, Melanogrammus aeglefinus and Coryphaenoides rupestris, and the species of fish belonging to the order Siluriformes, said enzymatic hydrolysis being carried out by means of an endopeptidase enzyme derived from Bacillus subtilis. The protein hydrolysate according to the invention makes it possible to maintain the bone mass or to stimulate bone growth through stimulation of osteoblast cell growth and inhibition of osteoclast cell growth.

摘要翻译： 本发明涉及具有感兴趣的生物活性的鱼蛋白水解产物，特别是对刺激和维持骨骼的影响。 鱼蛋白水解物的特征在于其通过酶水解至少一种选自鱼类Micromesistius poutassou，Clupea harengus，Scomber scombrus，Sardina pilchardus，Trisopterus esmarki，Trachurus spp，Gadus morhua，Pollachius virens，Melanogrammus 鳗鱼和Coryphaenoides rupestris，以及属于琉璃the属的鱼类，表示酶水解是通过源自枯草芽孢杆菌的内肽酶进行的。 根据本发明的蛋白质水解产物使得可以通过刺激成骨细胞生长和抑制破骨细胞生长来维持骨量或刺激骨生长。

公开(公告)号：US09308222B2

公开(公告)日：2016-04-12

申请号：US12845301

申请日：2010-07-28

申请人： Yun Kau Tam ,  Ge Lin

发明人： Yun Kau Tam ,  Ge Lin

IPC分类号： A61K33/06 ,  A23L1/303 ,  A23L1/304 ,  A61K31/593 ,  A61K33/30 ,  A61K35/02 ,  A61K45/06 ,  A23L1/302 ,  A23L1/29 ,  A61K31/19 ,  A61K35/60 ,  A23L2/02 ,  A61K9/20

CPC分类号： A61K33/06 ,  A23L2/02 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23L33/165 ,  A23L33/40 ,  A23V2002/00 ,  A61K9/20 ,  A61K9/2095 ,  A61K31/19 ,  A61K31/593 ,  A61K33/30 ,  A61K35/02 ,  A61K35/60 ,  A61K45/06 ,  A61K2300/00 ,  A23V2250/7106 ,  A23V2250/1642 ,  A23V2250/1578 ,  A23V2250/161 ,  A23V2200/306

摘要： The present invention provides formulas of elemental compositions encompassing acetate salts of calcium, magnesium and zinc along with vitamin D3. The acetate salts could be extracted from natural sources such as pearls, coral, and oyster or compounded using synthetic materials. The dosage and ratio of calcium to magnesium was estimated using in vitro and in vivo estimations. The dosage for promoting bone health and alleviation of osteoporosis is about a quarter to a third of the conventional dose.

摘要翻译： 本发明提供包含钙，镁和锌的乙酸盐以及维生素D3的元素组合物的配方。 乙酸盐可以从天然来源如珍珠，珊瑚和牡蛎中提取，或者使用合成材料进行复合。 使用体外和体内估计估计钙与镁的剂量和比例。 用于促进骨骼健康和缓解骨质疏松症的剂量约为常规剂量的四分之一至三分之一。

公开(公告)号：US09283252B2

公开(公告)日：2016-03-15

申请号：US13119382

申请日：2009-09-29

申请人： Daisuke Ochi ,  Hiroshi Tsuboi

发明人： Daisuke Ochi ,  Hiroshi Tsuboi

IPC分类号： C12N1/20 ,  A61K35/74 ,  A23L1/30 ,  C12R1/225

CPC分类号： A61K35/74 ,  A23L33/135 ,  A23V2002/00 ,  A23Y2220/37 ,  C12R1/225 ,  A23V2200/306

摘要： The present invention provides lactic acid bacteria having oxalic acid-degrading activity several times higher than those of conventionally known lactic acid bacteria having an oxalic acid-degrading activity, and uses thereof. Lactic acid bacteria capable of degrading a large amount of oxalic acid were screened from 132 strains of Lactobacillus lactic acid bacteria that have been independently isolated from feces and gastric juices of human adults. As a result, lactic acid bacteria having an oxalic acid degradation rate of 50% or more when cultured at 37° C. for 72 hours in a culture medium containing 10 mM oxalic acid at pH 6.5 at the start of culture were discovered.

摘要翻译： 本发明提供了具有比常规已知的具有草酸降解活性的乳酸菌高几倍的草酸降解活性的乳酸菌及其用途。 从132个来自人类粪便和胃液中独立分离的乳酸杆菌乳杆菌筛选能够降解大量草酸的乳酸菌。 结果发现，培养开始时，在含有10mM草酸的培养基中，在37℃培养72小时，草酸降解率为50％以上的乳酸菌。